Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1018 - The management and outcome of crizotinib resistant patients: comparison of patients who received ceritinib to those treated with chemotherapy or other oral TKI.


24 Nov 2018


Poster display - Cocktail


Swaratika Majumdar


Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425


S. Majumdar1, A. Agarwal1, V. Noronha1, A. Joshi1, V. Patil1, R. Kumar2, K. Prabhash1

Author affiliations

  • 1 Medical Oncology, Tata Memorial Hospital, 400081 - Mumbai/IN
  • 2 Pathology, Tata Memorial Hospital, 400081 - Mumbai/IN


Abstract 1018


Sequential use of ceritinib in crizotinib pretreated advanced ALK rearranged NSCLC is efficacious. Availability of ceritinib in resource constrained settings is limited.Sequential use of ceritinib in crizotinib pretreated advanced ALK rearranged NSCLC is efficacious. Availability of ceritinib in resource constrained settings is limited.


Retrospective analysis of a prospective audit of all patients with advanced NSCLC (approved by Institutional Ethics Committee of Tata Memorial Hospital, registered with Clinical Trials Registry India, CTRI CTRI/2013/01/003335; all patients signed a written informed consent). All patients with ALK rearranged advanced NSCLC, who progressed on crizotinib were included. Data cutoff date was 17th July 2018. OS was calculated from the date of presentation to the hospital to date of death from any cause.


Between March 2013 and April 2018, there were 100 patients. 62% were male with a median age of 50 years (IQR 21-68). 87% were never smokers and 80% had no comorbidities. 37% had received crizotinib as first line therapy. 65% had a single site progression, most commonly brain (25.5%). Overall, 38 patients received ceritinib at some point during therapy. Ceritinib was used in second line in 58% patients, third line in 29% and in fourth line and beyond in 13%. Other therapy consisted of chemotherapy (5%), crizotinib with chemotherapy (39%), crizotinib continuation (18%), Alectinib (1%) and no therapy (9%). Median follow-up of surviving patients was 50 months (range: 1 to 62). Median PFS of the patients who received ceritinib was 5 months (95%CI, 3.4 to 6.6). Median OS of the entire cohort was 30 months (95%CI, 23.6 to 36.4). The median OS of the patients who received ceritinib was 32 months (95%CI, 26.3 to 37.7) versus 29 months (95%CI, 21-37) for other therapies, p = 0.41 by log rank test.


In our cohort of patients with crizotinib resistant advanced NSCLC, there was no significant difference in OS and PFS between those who received ceritnib and those treated with chemotherapy/other TKI. In resource limited setting, chemotherapy or other TKI may be a practical alternative.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Tata Memorial Hospital, Parel, Mumbai.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.